EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Dung T Le, Luis A Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H O'Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud und 8 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.02.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Dung T Le und 19 weiteren Autor:innen. Beteiligte Einrichtung: Oncology, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA. Electronic address: dle@jhmi.edu. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Merck Sharp and Dohme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsDNA Mismatch RepairMicrosatellite InstabilityHumansAntibodies, Monoclonal, HumanizedBrain NeoplasmsNeoplastic Syndromes, Hereditary

Stichwörter der Autor:innen

Colorectal cancerMicrosatellite instabilityMismatch repairPembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Oncology, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA. Electronic address: dle@jhmi.edu.
  • Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Oncology, Asan Medical Center, Seoul, Republic of Korea.
  • Oncology, Asan Medical Center, Seoul, Republic of Korea; University of Ulsan, Ulsan, Republic of Korea.
  • Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium.
  • Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel.
  • Medical Oncology, University Medical Center Heidelberg, National Center for Tumor Diseases, Heidelberg, Germany.

Förderung

  • Merck Sharp and Dohme

Zitieren

APA

Le, D. T., Diaz, L. A., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O'Neil, B. H., Kavan, P., Yoshino, T., Guimbaud, R., Taniguchi, H., Élez, E., Al-Batran, S. E., Boland, P. M., Cui, Y., Leconte, P., Marinello, P., & André, T. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.02.016

Vancouver

Le DT, Diaz LA, Kim TW, Van Cutsem E, Geva R, Jäger D, et al. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.02.016

BibTeX
@article{Le2023,
  author = {Le, Dung T and Diaz, Luis A and Kim, Tae Won and Van Cutsem, Eric and Geva, Ravit and Jäger, Dirk and Hara, Hiroki and Burge, Matthew and O'Neil, Bert H and Kavan, Petr and Yoshino, Takayuki and Guimbaud, Rosine and Taniguchi, Hiroya and Élez, Elena and Al-Batran, Salah-Eddin and Boland, Patrick M and Cui, Yi and Leconte, Pierre and Marinello, Patricia and André, Thierry},
  title = {Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.02.016}
}
Kostenlos starten →